1 March 2003 in International Journal of Cardiology
1 June 2002 in Journal of Clinical Oncology
13 July 2021 in Nuclear Medicine and Molecular Imaging
1 November 2002 in Southern Medical Journal
AAAkindolapo O. Akinwande
1 January 2004 in Cardiology in Review
Coronary interventions have revolutionized the treatment of coronary artery disease (CAD). Stents, which were used initially for the complications arising from coronary angiography gradually, came to occupy a more prominent role in coronary interventions. However, restenosis remained a limiting factor from a therapeutic point of view. Recent development of drug-eluting stents is a step toward overcoming this problem. This development has elicited a great interest in both physician as well as patient communities. We have reviewed the available medical evidence regarding drug-eluting stents.
1 November 2020 in Journal of Endourology
Purpose: To investigate the safety of microwave ablation (MWA) as an emerging technology for treating small renal masses. Materials and Methods: Patients with renal masses treated at a high-volume center with MWA between March 2015 and June 2019 were retrospectively identified. Safety, changes in renal function, primary treatment efficacy, and the natural history of imaging characteristics of masses postablation were examined. Results: Forty-five patients underwent MWA during the study period. Median age was 71 years (range 31–87). Median RENAL nephrometry score was 6 (range 4–9) with mean tumor size 2.6 ± 0.7 cm. Thirty-three percent of tumors were within 4 mm of the collecting system. Median total microwave energy applied was 400 W (range 105–2600 W). There was no significant change in creatinine ( p = 0.21) or glomerular filtration rate (GFR) ( p = 0.09) from preoperative to postoperative day 1 (POD#1) levels. There was a statistically but not clinically significant decrease in hemoglobin from preoperative to POD#1 levels (estimated −0.06 from 7 days before procedure to POD#1, p = 0.02). There was no durable change in creatinine ( p = 0.16) or GFR ( p = 0.72) at median follow-up of 7.5 months. There were 4 (9%) complications: three Clavien grade 1 and one Clavien grade 3 that led to loss of the kidney. Tumor size decreased postoperatively by an estimated −0.03 cm/month (range 0–1.9 cm, p < 0.01). Initial technical success was 100%. Primary treatment efficacy was 94%. Conclusion: MWA shows promise as an alternative thermal ablative technique with excellent short-term outcomes.